Healthcare provider profile · identity verified

Angelo Sermas, MD

Neurology · COLLEGE STATION, TX · NPI 1891750592

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	270	58
Carbidopa-Levodopa	Carbidopa/Levodopa	229	47
Donepezil Hcl	Donepezil Hcl	195	47
Topiramate	Topiramate	173	39
Levetiracetam	Levetiracetam	144	34
Memantine Hcl	Memantine Hcl	134	28
Clonazepam	Clonazepam	116	19
Carbidopa-Levodopa Er	Carbidopa/Levodopa	94	20
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	80	12
Amantadine	Amantadine Hcl	77	12
Clobazam	Clobazam	72	suppressed
Tramadol Hcl	Tramadol Hcl	72	12
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	68	16
Nortriptyline Hcl	Nortriptyline Hcl	61	13
Aimovig Autoinjector	Erenumab-Aooe	60	suppressed
Baclofen	Baclofen	59	13
Rivastigmine	Rivastigmine Tartrate	58	suppressed
Lamotrigine	Lamotrigine	57	15
Primidone	Primidone	53	15
Modafinil	Modafinil	52	12
Pyridostigmine Bromide	Pyridostigmine Bromide	52	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	52	suppressed
Zonisamide	Zonisamide	52	14
Rasagiline Mesylate	Rasagiline Mesylate	50	suppressed
Dalfampridine Er	Dalfampridine	49	suppressed
Prednisone	Prednisone	48	11
Pregabalin	Pregabalin	48	16
Ropinirole Hcl	Ropinirole Hcl	48	suppressed
Rytary	Carbidopa/Levodopa	47	suppressed
Oxcarbazepine	Oxcarbazepine	41	suppressed
Bupropion Xl	Bupropion Hcl	40	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	40	suppressed
Duloxetine Hcl	Duloxetine Hcl	38	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	37	suppressed
Rizatriptan	Rizatriptan Benzoate	37	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	36	suppressed
Diazepam	Diazepam	30	suppressed
Emgality Pen	Galcanezumab-Gnlm	29	suppressed
Austedo	Deutetrabenazine	28	suppressed
Teriflunomide	Teriflunomide	28	suppressed
Dimethyl Fumarate	Dimethyl Fumarate	27	suppressed
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Lacosamide	Lacosamide	25	suppressed
Carbamazepine Er	Carbamazepine	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	22	suppressed
Tecfidera	Dimethyl Fumarate	22	suppressed
Promethazine Hcl	Promethazine Hcl	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	20	suppressed
Qulipta	Atogepant	19	suppressed
Sertraline Hcl	Sertraline Hcl	19	suppressed
Kesimpta Pen	Ofatumumab	18	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	18	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	18	suppressed
Propranolol Hcl Er	Propranolol Hcl	18	suppressed
Risperidone	Risperidone	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Fingolimod	Fingolimod Hcl	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Metoprolol Succinate	Metoprolol Succinate	17	suppressed
Ubrelvy	Ubrogepant	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Nurtec Odt	Rimegepant Sulfate	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Azathioprine	Azathioprine	15	suppressed
Glatiramer Acetate	Glatiramer Acetate	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Armodafinil	Armodafinil	13	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	12	suppressed
Rivastigmine	Rivastigmine	12	suppressed
Simvastatin	Simvastatin	12	suppressed
Diacomit	Stiripentol	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Neupro	Rotigotine	11	suppressed
Ropinirole Er	Ropinirole Hcl	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error